Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT01769196 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2013
- Completion date
- February 23, 2016
- Enrollment
- 544 (actual)
- Sites
- 175
Conditions
As the registry lists them; a condition with its own page is linked.